Phaseline

Targets › MAGE3

MAGE3 (Melanoma-associated antigen 3): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 2; Oncology; next expected readout Sep 2027.

Activator of ubiquitin ligase activity of RING-type zinc finger-containing E3 ubiquitin-protein ligases that acts as a repressor of autophagy. May enhance ubiquitin ligase activity of TRIM28 and stimulate p53/TP53 ubiquitination by TRIM28. (UniProt, P43357)

Open in Phaseline: the race on MAGE3, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Fondazione Ricerca TraslazionaleTedopi
Cancer vaccine inducing cytotoxic T-lymphocytes against tumor-associated antigens (CEA, p5
CEA, TP53, ERBB2, MAGE2, MAGE3Phase 2Metastatic Non Small Cell Lung CancerSep 2027

Conditions

Metastatic Non Small Cell Lung Cancer (1)

Modalities

mixed (1)

Companies

Fondazione Ricerca Traslazionale (1)

Related targets

CEA (1) TP53 (1) ERBB2 (1) MAGE2 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.